Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BerryTec is a dietary supplement marketed as a senolytic agent by FAME Pharmaceuticals Industry. Formulated as oral caplets, each dose contains 100 mg of strawberry fruit extract (standardized to the longevity flavonoid fisetin) and 50 mg of fenugreek seed extract. Fisetin acts as a senotherapeutic agent that selectively clears senescent cells (often referred to as 'zombie cells') to reduce age-related tissue dysfunction and inflammation. Additionally, fisetin is reported to activate sirtuin 1 (SIRT-1), increase intracellular glutathione levels, maintain mitochondrial function, and inhibit NF-kB pathways, thereby supporting healthy aging, neuroprotection, and tissue homeostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BerryTec.